Transcatheter mitral valve repair (TMVR) using the edge-to-edge technique with the Mitraclip® system is increasingly used to treat patients with mitral regurgitation (MR) and high surgical risk. We sought to assess outcomes of TMVR in patients with severe heart failure in New York Heart Association (NYHA) class IV.
Inclusion of patients accepted for TMVR between October 2015 and September 2018. Clinical and echocardiographic characteristics were assessed before and after procedure. Survival and survival-free from heart failure was evaluated with Kaplan-Meier´s method.
44 patients: 34 in NYHA class II-III, 10 in NYHA class IV (5 ambulatory IV, 5 hospitalised IV). There were no complications during procedure.
Basal characteristics of patients in each group are shown in table 1. Mean follow-up time of 267 days (interquartile range 102 – 655 days). Grade of MR before, immediately after procedure and at 6 month-follow-up are shown in figure 1, with no significant differences between groups.
At one year of follow-up all patients in the NYHA IV group were alive vs 84% of patients in the NYHA I-III group. Survival free from heart failure admission was 79.43% at one year in the NYHA IV group and 74.53% in the NYHA I-III group.
TMVR performed in advanced and acute descompensated heart failure patients is safe. Survival results and decrease in MR grade are maintained in this subgroup.